- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02955381
Restylane Silk Acne Scar Efficacy Evaluation Study
May 8, 2019 updated by: Schweiger Dermatology, PLLC
6 Month Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Small Particle Hyaluronic Acid to Treat Acne Scars Located on the Cheeks and Forehead
Randomized, double-blind, placebo-controlled, research pilot study.
30 subjects aged 22-55 years old of all skin types will be asked to sign an informed consent form prior to any study procedures.
Subjects must have at least 1 but up to 3 acne scars ≥3 mm or ≤ 10 mm located on the cheeks or forehead.
Subjects will receive one treatment (Restylane® Silk or Placebo) in each scar at day 0, and Month 1 (2 total treatments per scar during the study).
Subjects will be asked to come to 10 visits: Screening visit (up to 35 days prior to Baseline), Baseline (Day 0), Day 7, Day 14, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6 (study exit visit).
The treatment area will be evaluated at each visit by the unblinded investigator regarding erythema, bruising, inflammation, itching, stinging/burning, brightness, fullness, smoothness, and clarity.
Safety and adverse events will be captured at each visit only by the unblinded investigator.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Randomized, double-blind, placebo-controlled, research pilot study.
30 subjects aged 22-55 years old of all skin types will be asked to sign an informed consent form prior to any study procedures.
Subjects must have at least 1 but up to 3 acne scars ≥3 mm or ≤ 10 mm located on the cheeks or forehead.
Subjects will receive one treatment (Restylane® Silk or Placebo) in each scar at day 0, and Month 1 (2 total treatments per scar during the study).
Subjects will be asked to come to 10 visits: Screening visit (up to 35 days prior to Baseline), Baseline (Day 0), Day 7, Day 14, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6 (study exit visit).
The blinded investigators will evaluate the target scar using the Acne Scar Rating Scale (ASRS), rate the target acne scar regarding treatment effect on a -5 ("Markedly worse"), to 0 ("Neutral Improvement"), to 5 (Markedly Improved (Clear or nearly clear)) point scale, and evaluate the skin quality (regarding brightness, fullness, smoothness, and clarity).
Subjects will give the acne scar a score on the subject VAS acne scar satisfaction scale marking between 0 ("Not satisfied with Acne Scar at Day 0") and 10 ("Extremely Satisfied with Acne Scar at Day 0").
The treatment area will be evaluated at each visit by the unblinded investigator regarding erythema, bruising, inflammation, itching, stinging/burning, brightness, fullness, smoothness, and clarity.
The subject will have their vital signs taken, complete a symptom diary (only if the subject experiences side effects or adverse events), complete a DLQI, and have photos (VECTRA and 2D digital photographs) taken of the treatment area.
Efficacy measures will only be completed by the blinded investigator.
Safety and adverse events will be captured at each visit only by the unblinded investigator.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10022
- Schweiger Dermatology, PLLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non-pregnant female subjects on an acceptable form of birth control aged 22-55 years of age.
- Willing to refrain from undergoing any procedures to repair or augment any acne scar in the treatment area during the study.
- Female subjects with a negative pregnancy test confirmed at screening and on an acceptable form of birth control. Acceptable forms of birth control on this study include oral or injectable contraceptive, contraceptive patches, Depo-Provera, NuvaRing, Implanon, double barrier methods, IUD, same sex partner, or abstinence. Males will be required to use an acceptable method of birth control: vasectomy, double-barrier method, condom with spermicidal lube, or abstinence.
- Signed informed consent prior to conducting any study procedures.
- Willing to refrain from undergoing any cosmetic procedures in the treatment area during the study.
- At least one acne scar located on the cheeks or forehead to be ≥ 3 mm and ≤ 10 mm in diameter, and rated as ≥3 on the ASRS at day 0. Subjects may have up to three qualifying acne scars determined eligible for treatment at screening.
- Acne scars that are classified as either ice pick, rolling, or boxcar acne scars.
- ≤15 pustules/papules on the face at the time of screening and ≤ 2 nodules, and no cysts at Baseline.
- Willing to attend all study visits and comply with protocol
Exclusion Criteria:
- Subjects with active cystic acne at screening (> 2 nodules or any cysts present at Baseline).
- Use of antibiotics 2-weeks prior to screening.
- Use of retinoids 2-weeks prior to screening.
- Use of salicylic acid or benzoyl peroxide 7 days prior to screening.
- Excessive facial hair, skin conditions, facial tattoos, or other dermatologic marks that would obscure the treatment area.
- Use of Isotretinoin (Accutane) 6 months prior to screening.
- Semi-permanent or permanent injection in the face 3 months prior to screening.
- History of bleeding disorders.
- Use of blood thinners (i.e warfarin (Coumadin), clopidogrel bisulfate (Plavix), etc.) 1 month prior to screening.
- Acne scars that are considered post-inflammatory erythematous, post-inflammatory hyperpigmentation, varicella (chicken pox) scars, or perifollicular elastolysis will not be allowed to be identified as the target acne scars. These types of scars are still allowed to be present but cannot be selected.
- Acne scars that are located in the glabella and temple regions. Acne scars located in these regions will not be allowed to be selected as a target or additional acne scar. As well, scars located in these areas will not be allowed to be treated during the study. Subjects are allowed to have acne scars located in these areas but cannot have them selected for evaluation or treated during the study.
- Laser or light (red and blue) treatments for acne 3 months prior to screening.
- Resurfacing procedures (CO2 , Erbium, Fraxel, etc.) performed 6 months prior to screening.
- Any chemical peels in the last 30 days prior to screening.
- Hypersensitivity to amid-type local anesthetics.
- Any cortisol steroid or ILK injection 30 days prior to screening
- Subjects with a history of diabetes.
- Any medical condition or diagnosis which in the investigator's opinion would disqualify them from the research study.
- History of abuse with the use of alcohol or drugs.
- Participation in a clinical trial or use of an investigational product in the past 30 days.
- Subjects who are considered health risks for participation in the study or the investigator determines not to be suitable.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Restylane Silk, 1.0 ml
Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead.
Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study).
Subjects will remain blinded to the treatment administered to them during these visits.
|
Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
|
Placebo Comparator: Placebo (Saline), 1.0 ml
Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead.
Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study).
Subjects will remain blinded to the treatment administered to them during these visits.
|
Simple saline solution.
To be used as placebo (control).
No active ingredients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1 grade improvement of ASRS from baseline
Time Frame: Baseline-6 Months post first injection.
|
The primary endpoint is a one grade improvement of the acne scar from baseline as rated on the ASRS.
|
Baseline-6 Months post first injection.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Statistically significant improvement of the acne scar from baseline
Time Frame: Baseline-6 Months post first injection.
|
A significant improvement of the acne scar from baseline as rated by the
|
Baseline-6 Months post first injection.
|
Statistically significant improvement of the skin quality from baseline
Time Frame: Baseline-6 Months post first injection.
|
A significant improvement of the skin quality of the treatment area as rated by the investigator using the skin quality assessment scale.
|
Baseline-6 Months post first injection.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Statistically significant acne scar area reduction from baseline.
Time Frame: Baseline-6 Months post first injection.
|
The first exploratory endpoint is a significant reduction of acne scar area as measured by the VECTRA system 6 months post first treatment
|
Baseline-6 Months post first injection.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eric S Schweiger, M.D., CEO & Chief Medical Officer
- Study Director: Margaret J Tropeano, BS, Clinical Research Director
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Brandt FS, Cazzaniga A. Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging. 2008;3(1):153-9. doi: 10.2147/cia.s2135.
- Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am. 2007 Feb;15(1):63-76, vii. doi: 10.1016/j.fsc.2006.11.002.
- Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol. 2001 Jul;45(1):109-17. doi: 10.1067/mjd.2001.113451.
- Fife D. Practical evaluation and management of atrophic acne scars: tips for the general dermatologist. J Clin Aesthet Dermatol. 2011 Aug;4(8):50-7.
- Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994 Jul;19(4):303-8. doi: 10.1111/j.1365-2230.1994.tb01200.x.
- Koo JY, Smith LL. Psychologic aspects of acne. Pediatr Dermatol. 1991 Sep;8(3):185-8. doi: 10.1111/j.1525-1470.1991.tb00856.x.
- Rivera AE. Acne scarring: a review and current treatment modalities. J Am Acad Dermatol. 2008 Oct;59(4):659-76. doi: 10.1016/j.jaad.2008.05.029. Epub 2008 Jul 26.
- Tsao SS, Dover JS, Arndt KA, Kaminer MS. Scar management: keloid, hypertrophic, atrophic, and acne scars. Semin Cutan Med Surg. 2002 Mar;21(1):46-75. doi: 10.1016/s1085-5629(02)80719-2. No abstract available.
- Sadick NS, Palmisano L. Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat. 2009;20(5):302-7. doi: 10.1080/09546630902817879.
- Lizzul PF, Narurkar VA. The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation. J Drugs Dermatol. 2010 May;9(5):446-50.
- Fife D, Zachary CB. Combining techniques for treating acne scars. Current Dermatology Reports. 2012;1:82-88.
- Werschler, Phillip, et al.
- Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg. 2008 Jun;34 Suppl 1:S92-9. doi: 10.1111/j.1524-4725.2008.34249.x.
- Hession MT, Graber EM. Atrophic acne scarring: a review of treatment options. J Clin Aesthet Dermatol. 2015 Jan;8(1):50-8.
- Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg. 1998 Dec;24(12):1317-25. doi: 10.1111/j.1524-4725.1998.tb00007.x.
- Werschler WP, Few JW, Jacob CI, Joseph JH, Spencer JM, Taub AF. Advancing the Care of Post-Acne Scarring: Expert Insights Into New Treatment Options. J Drugs Dermatol. 2016 May 1;15(5):518-25.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2017
Primary Completion (Actual)
April 18, 2019
Study Completion (Actual)
April 18, 2019
Study Registration Dates
First Submitted
November 2, 2016
First Submitted That Met QC Criteria
November 3, 2016
First Posted (Estimate)
November 4, 2016
Study Record Updates
Last Update Posted (Actual)
May 10, 2019
Last Update Submitted That Met QC Criteria
May 8, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SDG 02-2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
This is an investigator initiated study and will use the primary data to create a final data report.
Individual patient data will not be available to other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Scars
-
Ulthera, IncCompleted
-
IBSA Farmaceutici Italia SrlDerming SRLCompletedAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
Northwestern UniversityActive, not recruiting
-
Massachusetts General HospitalUnknown
-
Goldman, Butterwick, Fitzpatrick and GroffCynosure, LLCNot yet recruitingAcne Scars
-
Cynosure, Inc.Completed
-
Massachusetts General HospitalAmerican Society for Dermatologic SurgeryCompleted
-
Dongtan Sacred Heart HospitalUnknownAcne ScarsKorea, Republic of
-
Skincare Physicians of Chestnut HillCandela CorporationCompletedAcne Scars | AcneUnited States
-
Alma Lasers Inc.CompletedAcne Scars | WrinklesUnited States
Clinical Trials on Restylane Silk, 1.0 ml
-
Nashville Centre for Laser and Facial SurgeryCompletedTear Trough Deformity
-
Amanda D. Spear, CCRCCompleted
-
Skin Laser & Surgery SpecialistsCompletedPhotoaged Thinning of the Hands
-
Goldman, Butterwick, Fitzpatrick and GroffUnknown
-
DeNova ResearchCompletedLip RejuvenationUnited States
-
Goldman, Butterwick, Fitzpatrick and GroffUnknown
-
University of PennsylvaniaGalderma R&DActive, not recruiting
-
Prollenium Medical Technologies Inc.Symbio, LLCCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany